Cardio TTRansform
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Cardiomyopathy
Study Purpose
ION-682884 is an investigational drug. 'Investigational' means that ION-682884 is not yet approved for use in any settings outside of clinical research studies like this one and is considered experimental. ION-682884 reduces the level of TTR (transthyretin cardiac amyloidosis) in the blood of animals and healthy volunteers tested to date. TTR is a type of protein in your blood. Reducing the amount of TTR in your blood may reduce the amount of amyloid deposits in your body and may keep your cardiomyopathy from getting worse over time. However, it is not known if ION-682884 will help your cardiomyopathy. The purpose of this study is to evaluate the safety of ION-682884 and determine if it can help people with this type of cardiomyopathy.
Locations
UH Portage Medical Center
6847 North Chestnut Street
Ravenna Ohio, 44266
UH Minoff Health Center at Chagrin Highlands
3909 Orange Place
Orange Village OH, 44122
UH Ahuja Medical Center
3999 Richmond Road
Beachwood OH, 44122
UH Bedford Outpatient Campus
44 Blaine Avenue
Bedford OH, 44146
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: STUDY20210847
- StudyID: 2021-0666
- ClinicalTrials.gov: NCT04136171
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422